Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Purchased by Prudential Financial Inc.

Prudential Financial Inc. raised its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 23.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,945 shares of the company’s stock after purchasing an additional 7,000 shares during the quarter. Prudential Financial Inc.’s holdings in Xeris Biopharma were worth $125,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of XERS. R Squared Ltd purchased a new position in shares of Xeris Biopharma in the fourth quarter valued at $42,000. Cibc World Markets Corp acquired a new position in Xeris Biopharma in the 4th quarter worth $44,000. Raymond James Financial Inc. purchased a new position in Xeris Biopharma in the 4th quarter valued at about $45,000. Virtu Financial LLC acquired a new stake in shares of Xeris Biopharma during the fourth quarter valued at about $58,000. Finally, Sunpointe LLC purchased a new stake in shares of Xeris Biopharma during the fourth quarter worth about $71,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Craig Hallum increased their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research note on Friday, March 7th. Leerink Partners lifted their price target on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research note on Friday, March 7th. Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Xeris Biopharma currently has an average rating of “Moderate Buy” and an average target price of $6.10.

Insiders Place Their Bets

In related news, insider Beth Hecht sold 40,000 shares of the stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $5.43, for a total transaction of $217,200.00. Following the sale, the insider now owns 1,353,510 shares in the company, valued at $7,349,559.30. This represents a 2.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.56% of the stock is currently owned by corporate insiders.

Xeris Biopharma Trading Up 5.3 %

Shares of XERS opened at $4.16 on Friday. The firm has a market cap of $640.39 million, a price-to-earnings ratio of -9.24 and a beta of 1.37. Xeris Biopharma Holdings, Inc. has a 52 week low of $1.69 and a 52 week high of $6.07. The stock has a 50 day moving average of $4.39 and a 200-day moving average of $3.65.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.